Appeal No. 94-2113
Application 07/801,207
has additionally rejected claims 1 to 4, 11 to 16 and 19 to 28 as
being unpatentable under 35 U.S.C. § 103 over the prior art, in
particular the combination Hoffman et al. and Aberg et al.
The examiner found, and applicants do not seem to disagree,
that Cecil discloses that high cholesterol levels and
hypertension are major risks factors for atherosclerosis.
(Appeal Brief, page 5; Examiner’s Answer, page 4).
The examiner found, and applicants do not seem to disagree,
that Costa et al., Weinstein et al. and Someya et al. describe
that hypertension accelerates the progress of atherosclerosis and
that atherosclerotic mammals treated with ACE inhibitors showed a
regression in their atherosclerotic symptoms. (Examiner’s Answer,
page 4).
The examiner found, and applicants do not seem to disagree,
that Hoffman et al. describes the use of cholesterol lowering
drugs to treat hypercholesterolemia, a known risk factor in
atherosclerosis. (Examiner’s Answer, page 4).
The examiner found, and applicants do not seem to disagree,
that Aberg et al. describes ACE inhibitors *** to be useful in
stabilizing or causing a regression of atherosclerosis.
(Examiner’s Answer, page 5).
The only salient argument that is advanced by the applicants
against the rejections is that none of the references describe or
suggest the use of a combination of a cholesterol lowering drug
- 3 -
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007